Onglyza Lawsuit – Heart Failure

Onglyza lawsuit imageCan I file a lawsuit if I had problems with Onglyza?

Onglyza is a type 2 diabetes drug made by AstraZeneca. Though some people have had success treating their disease with the drug, others have had heart problems after using Onglyza. Some are taking legal action against the drug’s maker and have filed Onglyza lawsuits.

Onglyza has been shown to increase the risk for certain cardiovascular events and create potentially fatal complications.

What is Onglyza?

Onglyza is a type 2 diabetes drug that was approved by the FDA in 2009. It helps to control blood sugar levels. It works by increasing levels of natural substances called incretins, which control blood sugar by increasing insulin release, especially after a meal. Incretins also decrease the amount of sugar your liver makes.

Despite the drug’s approval, the FDA recently issued a safety alert concerning Onglyza and its sister medication, Kombiglyze, calling on the drugs’ manufacturer to include a warning in prescribing information. Some are even calling for the drug’s removal from the US market.

There has been ongoing concern for Onglyza since a 2013 study showed similar medications could have a link to higher than normal rates of pancreatic cancer in users. You should contact your doctor right away if you have any symptoms that could be linked to pancreas health, including severe stomach/abdominal pain which may spread to the back, and or nausea or vomiting that doesn’t stop.

Onglyza’s other side effects include:

  • Joint pain
  • Low blood sugar, especially if using Onglyza with other anti-diabetic medications
  • High blood sugar
  • Allergic reaction

FDA Warns of Link between Onglyza and Increased Risk for Heart Failure

In April 2015 an FDA panel voted to require AstraZeneca to place a warning on Onglyza’s label to warn patients and doctors of a possible increased risk of heart failure.

The decision came after reviewing data from the SAVOR study. Of the study’s 16,000 subjects, 1,222 reported a major cardiovascular event. SAVOR results actually proved AstraZeneca met the threshold for cardiovascular episodes which needed to have an occurrence rate of less than 30 percent (the study showed a rate of 27 percent). Despite “success,” the FDA requested more information related to the death rate for Onglyza users and voted in favor of updating Onglyza’s labeling with a warning.

Onglyza users should be aware of and report any and all heart health symptoms to their doctor, including:

  • Breathing difficulty
  • Fatigue
  • Swelling of hands, feet, or ankles
  • Persistent cough
  • Wheezing
  • Irregular heart rate

Onglyza Lawsuits

In addition to the injuries caused by Onglyza, legal claims against AstraZeneca include:

  • Manufacturing of a dangerous medication
  • Failure to adequately warn the medical community and the public about possible dangers
  • Improper marketing of a medication
  • Marketing of a drug despite awareness of danger

If you or a loved one experienced complications after using Onglyza, you might be entitled to compensation for medical care, pain and suffering, and lost wages

Type 2 diabetes drugs are notorious for side effects. Despite the success some patients have with these drugs, many have suffered severe side effects. In some cases, side effects proved deadly.

Onglyza has created problems for many users and anyone using or considering use of this drug should be aware of the danger. If you or a loved one has suffered a heart health event because of Onglyza use, you have a right to take legal action.

View Sources
  1. AstraZeneca, (2015), Onglyza Prescribing Information, AstraZeneca, Accessed on 27 July 2015 https://www.onglyza.com/
  2. AstraZeneca, (14 April 2015), FDA Advisory Committee reviews SAVOR outcomes study results for ONGLYZA® (saxagliptin) and KOMBIGLYZE® XR (saxagliptin and metformin HCI extended-release), AstraZeneca, Accessed on 27 July 2015 http://www.astrazeneca.com/Media/Press-releases/Article/20150414-fda-committee-reviews-savor
  3. Ault, A., (14 April 2015) FDA Panel Backs New Safety Warnings on Two Diabetes Drugs, Medscape, Accessed on 27 July 2015 http://www.medscape.com/viewarticle/843179#vp_2
  4. Barber, J., (10 April 2015), FDA staff suggest AstraZeneca's diabetes drug Onglyza linked to higher rate of death, FirstWord Pharma, Accessed on 27 July 2015 http://www.firstwordpharma.com/node/1274816#axzz3h6ueRxBy
  5. Butler, A. E., et al., (2013), Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors, Diabetes, Accessed on 27 July 2015 http://diabetes.diabetesjournals.org/content/early/2013/03/17/db12-1686.abstract?sid=c292a1eb-fefa-4077-927d-651738e22e43
  6. European Medicines Agency, (26 August 2013), Investigation into GL-1-based diabetes therapies concluded, EMEA, Accessed on 27 July 2015 http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001856.jsp&mid=WC0b01ac058004d5c1
  7. Food and Drug Administration (11 February 2014), FDA Drug Safety Communication: FDA to review heart failure risk with diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR), U.S. Food and Drug Administration, Accessed on 27 July 2015 http://www.fda.gov/Drugs/DrugSafety/ucm385287.htm
  8. Hirschler, B., (02 September 2013), Doctors get good and bad safety news on diabetes drugs, Reuters, Accessed on 27 July 2015 http://www.reuters.com/article/2013/09/02/us-heart-diabetes-idUSBRE98103I20130902
  9. McDougall, C., et al., (2011), Drugs for Diabetes: Part 5 DPP-4 inhibitors, British Journal of Cardiology, Accessed on 27 July 2015
  10. Perry, S, (10 June 2013), New generation of diabetes drugs raising more concerns, Minnesota Post, Accessed on 27 July 2015 http://www.minnpost.com/second-opinion/2013/06/new-generation-diabetes-drugs-raising-more-concerns
  11. Scirica, B., et al., (03 October 2013), Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, New England Journal of Medicine, Accessed on 27 July 2015 http://www.nejm.org/doi/full/10.1056/NEJMoa1307684
  12. Staton, T., (09 April 2015), AZ's Onglyza has most to lose at FDA safety confab, analysts say, FiercePharma, Accessed on 27 July 2015 http://www.fiercepharma.com/story/azs-onglyza-has-most-lose-fda-safety-confab-analysts-say/2015-04-09
  13. WebMD http://www.webmd.com/drugs/2/drug-152753/onglyza-oral/details